What Peptides Can Compounding Pharmacies Legally Sell in 2026?

A current guide to the FDA rules that decide which peptides a compounding pharmacy may legally prepare, what the 2026 Category 2 removals did and did not change, and how to check a source before you trust it.

By Jeff Nunn. Originally published October 24, 2025. Updated June 3, 2026.

What changed in 2026:

In April the FDA removed 12 peptides from its Category 2 restricted list, including BPC-157, TB-500, KPV, MOTs-C, Semax, and Epitalon, because the groups that first nominated them withdrew those nominations. Removal from the restricted list is not the same as permission to compound. All 12 now sit in a holding pattern, waiting on an FDA advisory committee review set for late July 2026 and the rulemaking that would have to follow. For the politics behind the shift, the meeting agenda, and the full timeline through 2027, see our companion piece on RFK Jr.'s peptide war and the FDA. For what is and is not allowed today, read on.

Quick answers

• Are compounding pharmacy peptides legal?
• Some are. Most are not. Legality turns on whether a specific peptide is on the FDA's 503A or 503B Bulks List, is a component of an FDA-approved drug, or has an official quality standard published in the U.S. Pharmacopeia.
• Can BPC-157 be legally compounded right now?
• No. It left the restricted Category 2 list on April 22, 2026, but it has not been added to the list of substances a pharmacy may compound from. That gap is the whole story.
• Are compounded peptides FDA-approved?
• No. "FDA-approved" and "legal to compound" are different statuses. Compounded drugs are never FDA-approved.
• Can I still get compounded semaglutide or tirzepatide?
• Generally no. Both shortages resolved and the temporary windows closed. Narrow exceptions exist for documented clinical need.
• What peptides can a pharmacy legally compound today?
• A short list: oxytocin, vasopressin, cosyntropin, vasoactive intestinal peptide, and GHK-Cu in non-injectable forms.
• Are compounding pharmacy peptides legal?
• Some are, most are not, and the rules moved in April 2026. Compounding pharmacies work under Section 503A and Section 503B of the Federal Food, Drug, and Cosmetic Act. Together these sections create a narrow legal lane for preparing drugs that are not sold as FDA-approved products. For peptides, that lane has three gates. A peptide must clear at least one of them:

It is on the FDA's 503A Bulks List, the roster of bulk drug substances a 503A pharmacy may compound from (or its 503B equivalent), or It is a component of an FDA-approved drug (this is where the shortage exception lives), or It is the subject of a USP/NF monograph, an official quality standard in the U.S. Pharmacopeia and National Formulary.

A peptide that clears none of these three gates cannot be lawfully compounded for human use. That holds no matter who prescribes it, whether the patient consents, or how reputable the pharmacy is otherwise. The April 2026 changes did not touch this rule. What they changed is which peptides can clear gate one.

Can a pharmacy legally sell BPC-157 right now?

• As of June 3, 2026: no. Despite coverage that suggests otherwise, BPC-157 cannot be lawfully compounded under Section 503A today.

Here is where the confusion starts. BPC-157 sat in the FDA's Category 2 restricted list from September 2023 until April 22, 2026. On that date the FDA updated its 503A categories document to drop BPC-157 from Category 2, because the original nominators pulled their nominations. The peptide is off the restricted list. It has also not been added to the 503A Bulks List. Leaving the restricted list does not put a substance on the permitted list; those are two different actions, and only the second one makes compounding lawful.

To actually become compoundable, BPC-157 has to be added to the 503A Bulks List, and that addition runs through a slow process: the advisory committee reviews it, the FDA decides whether to accept the recommendation, then the agency publishes a proposed rule, opens a public comment period, reviews the comments, and issues a final rule. Under normal timelines that takes more than a year after the committee meets. The realistic earliest window for lawful BPC-157 compounding is mid-to-late 2027. Any pharmacy compounding it before then is working outside the law. The same logic applies to TB-500 and the rest of the 12 peptides that left Category 2 in April.

The two compounding lanes: 503A and 503B

The two categories serve different purposes and follow different rules.

503A covers traditional compounding pharmacies. They need a patient-specific prescription for each preparation. State boards of pharmacy handle most day-to-day oversight, with the FDA above them. When 503A conditions are met, these pharmacies are exempt from full Current Good Manufacturing Practice, the FDA's drug-manufacturing quality standard usually shortened to cGMP. Interstate shipping is capped at 5 percent of total prescriptions unless the state has a formal agreement with the FDA. They cannot mass-produce or stock for general office use.

503B covers outsourcing facilities. These register with the FDA, meet full cGMP standards, and can make larger batches for office use without an individual prescription per unit. They ship across state lines without the 5 percent cap, and they face FDA inspections and adverse-event reporting.

The two Bulks Lists are not the same. A peptide added to one is not automatically eligible under the other. That detail matters right now, because the July 2026 review is focused on the 503A side. The FDA has said little about whether the 12 peptides that left Category 2 will be considered for the 503B list. Outsourcing facilities should plan for that gap rather than assume parity.

How the FDA sorts nominated substances

Under its interim 503A policy, the FDA places nominated bulk drug substances into three working buckets:

Category 1 covers substances under review that the agency has not flagged as a significant safety risk. The FDA uses enforcement discretion here, meaning it chooses not to act against compounding while review continues, as long as the substance comes from an FDA-registered facility with a valid certificate of analysis.

Category 2 covers substances the FDA has flagged as potentially presenting significant safety risks. Enforcement discretion does not extend to them. They cannot be lawfully compounded under the interim policy.

Category 3 covers substances the FDA cannot evaluate for lack of information. They cannot be compounded either.

Current status of the disputed peptides (June 2026)

The table below reflects where each peptide in the long-running dispute stands today. The milestone column is deliberately short; for the meeting agenda, the specific indications under review, and the full procedural calendar through 2027, see the companion piece on the FDA peptide fight.

What a pharmacy can actually compound today

The list of peptides a 503A pharmacy can lawfully compound right now is short. These have been eligible for years and remain so with a valid prescription:

Oxytocin Vasopressin Cosyntropin Vasoactive intestinal peptide (VIP), a Category 1 substance under the interim policy GHK-Cu in non-injectable forms only, which the FDA is adding back to Category 1 per its May 14, 2026 update, covering topical and cosmetic preparations

Even Category 1 status does not let a pharmacy buy from a "research chemical" seller. Compounding these requires pharmaceutical-grade active ingredient from an FDA-registered facility, with a valid certificate of analysis for every lot.

The shortage exception, now closed for the GLP-1 drugs

A separate pathway, under Section 506E of the Act, lets pharmacies prepare copies of an FDA-approved drug while that drug is on the FDA's official shortage list. This was the legal basis for compounded semaglutide and tirzepatide during 2023 and 2024. Both shortages have since resolved.

As of the FDA's April 1, 2026 supply update: semaglutide is out of shortage and compounding is prohibited; tirzepatide is out of shortage and compounding is prohibited; dulaglutide injection remains in shortage, so compounding may be permissible; liraglutide injection remains in shortage, so compounding may be permissible. The lesson from the GLP-1 chapter is simple. Shortage exceptions are temporary, and once a shortage resolves the FDA moves quickly. Any pharmacy still selling compounded semaglutide or tirzepatide in mid-2026 is operating outside the law, whatever the marketing says.

The picture sharpened again on April 30, 2026, when the FDA proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound them. Liraglutide can still be compounded by a 503B facility for now, because it remains on the shortage list, but the proposal signals that large-scale compounding of these three drugs has no long-term future. The comment window on that proposal runs through late June 2026.

Restrictions that apply even when a peptide is eligible

Clearing a gate is not the end of it. Eligible compounds still carry conduct rules:

No claims of safety, efficacy, or sameness with an FDA-approved drug No "same as" or "bioidentical to" branded-product language, a rule that bites hardest in the GLP-1 space No before-and-after photos or testimonials that imply an outcome No dosing protocols or treatment guides on a pharmacy website No general weight-loss, performance, or anti-aging claims Patient-specific prescriptions for 503A work, with no office-use stockpiles Sterile-compounding standards under USP General Chapter 797, the U.S. Pharmacopeia standard for sterile preparations, for any injectable Interstate sales capped at 5 percent for 503A facilities without a state agreement A certificate of analysis for every active-ingredient lot, from an FDA-registered source

These promotional limits will apply to the disputed peptides too, if and when they reach Category 1. There is no reason to expect a softer posture for peptide marketing than for anything else.

Enforcement in 2026

The FDA has not eased up on compounding enforcement this year. In the twelve months ending March 2026, the agency issued more than 80 warning letters to telehealth companies over misleading compounded-GLP-1 marketing. A single action on March 3, 2026 produced 30 of them. The violations cited a consistent set of problems: claims implying the product was the same as an approved drug, language that hid where the product was sourced, branded telehealth marketing of drug products without proper qualification, and efficacy claims with no basis.

The signal matters for peptides specifically, because the same framework will govern any peptide that reaches Category 1. Pharmacies and telehealth platforms eyeing the peptide space should expect close reading of their marketing language, with warning letters as a first step and stronger action for repeat or egregious cases.

Workarounds that tend to fail

The April removals set off a wave of marketing that misstates the legal status of the affected peptides. The common workarounds, all of which the FDA has signaled it will pursue:

"For research use only" labeling, which does not exempt a seller from the Act when the product is marketed for human use Salt-form sourcing, such as a different counter-ion of the same molecule, which does not resolve the underlying ingredient-characterization concerns Telemedicine paired with a 503A prescription, which still requires a real prescriber-patient relationship and a peptide that is actually eligible Crypto or offshore payment, which changes nothing about the legality of the compound "Veterinary use" labeling, now scrutinized hard when the product flows to human-use channels "Same as Ozempic or Wegovy" claims, named directly in the March 2026 warning letters Selling the 12-peptide list items now, before rulemaking, which the legal pathway does not allow Naturopathic or homeopathic framing, which does not exempt a product from drug-marketing rules

The pattern is steady. Every workaround tried so far has eventually drawn FDA attention.

What this means for you right now

For patients. Do not assume your pharmacy can fill a BPC-157, TB-500, or similar prescription in 2026. Legally, it cannot. A pharmacy willing to fill one anyway is telling you something about its compliance posture. GHK-Cu in non-injectable form is the single peptide that did just get more accessible: topical creams, serums, and hair preparations using it are eligible for 503A compounding. Before you commit to any compounded peptide, check your state board of pharmacy for licensure, ask for the certificate of analysis, and confirm the active ingredient comes from an FDA-registered source.

For clinicians. Prescribing ahead of the rules, in anticipation of a change, creates compliance exposure for both you and the pharmacy, even if the pharmacy is willing. The standard process has to finish first.

For pharmacies and outsourcing facilities. The 503A lane is the focus of the current review; 503B is conspicuously absent, so plan separately for it. Build pharmaceutical-grade ingredient supply in parallel with the rulemaking, because a finished rule without a qualified supply chain is just paperwork. And expect the promotional limits to stay strict regardless of how the list shakes out.

How to tell a legitimate compounding pharmacy from a risky one

Signals of a compliant operation: a visible state pharmacy license number; National Drug Code numbers on compounded products; membership in bodies like PCCA or the Alliance for Pharmacy Compounding; documented USP 797 sterile-compounding practice; willingness to share a certificate of analysis with HPLC testing results; a required patient-specific prescription; and no efficacy claims, dosing guides, or comparisons to branded drugs.

Red flags: dosing guides or treatment protocols on the site, before-and-after photos, "same as" branded-drug claims, "research use only" labeling paired with consumer marketing, crypto-only or offshore payment demands, and any currently restricted peptide offered for sale. You can confirm license status directly through your state board of pharmacy.

Sources and monitoring

FDA: 503A Bulk Drug Substances FDA: 503A Categories document (updated May 14, 2026) FDA: Substances in Compounding That May Present Significant Safety Risks FDA: GLP-1 Compounding Policy Update (April 1, 2026) FDA: Proposed 503B Bulks List exclusion of semaglutide, tirzepatide, liraglutide (Federal Register, May 1, 2026) FDA: Telehealth warning letters (March 3, 2026) USP General Chapter 797 (sterile compounding standards) Drug Quality and Security Act of 2013

This guide is updated as the FDA's primary sources change.

Where to buy: vetted sources only. Compounding rules and chemical-supplier rules are two different worlds, and purity is the whole game in both. We track which research peptide vendors publish per-batch testing and keep verified discount codes current for each one. See the Vendor Directory and Coupon Codes

FAQ

Disclaimer:

This article is for informational and educational purposes only and does not constitute legal, medical, or professional advice. The information provided is based on FDA regulations and guidance documents current as of the publication date, but pharmaceutical compounding laws are subject to frequent changes and updates.

Not Legal Advice: This content should not be relied upon as legal counsel. Compounding pharmacies, healthcare providers, and businesses should consult with qualified legal professionals and regulatory experts before making compliance decisions.

Not Medical Advice: This article does not provide medical recommendations or endorse any specific treatments. Patients should consult with licensed healthcare providers regarding their individual medical needs and treatment options.

No Warranty: While we strive for accuracy, we make no representations or warranties regarding the completeness, accuracy, or timeliness of the information provided. Regulatory guidance can change without notice, and readers are responsible for verifying current regulations with the FDA and relevant state boards.

Use at Your Own Risk: The author and publisher assume no liability for actions taken based on the information in this article. Violation of FDA regulations can result in serious legal consequences including fines, criminal prosecution, and loss of professional licenses.

Always verify current FDA guidance, consult qualified legal and medical professionals, and review the most recent FDA Bulks Lists and shortage declarations before making any decisions related to peptide compounding.

Disclaimer:

This article is for informational and educational purposes only and does not constitute legal, medical, or professional advice. The information provided is based on FDA regulations and guidance documents current as of the publication date, but pharmaceutical compounding laws are subject to frequent changes and updates.

Not Legal Advice: This content should not be relied upon as legal counsel. Compounding pharmacies, healthcare providers, and businesses should consult with qualified legal professionals and regulatory experts before making compliance decisions.

Not Medical Advice: This article does not provide medical recommendations or endorse any specific treatments. Patients should consult with licensed healthcare providers regarding their individual medical needs and treatment options.

No Warranty: While we strive for accuracy, we make no representations or warranties regarding the completeness, accuracy, or timeliness of the information provided. Regulatory guidance can change without notice, and readers are responsible for verifying current regulations with the FDA and relevant state boards.

Use at Your Own Risk: The author and publisher assume no liability for actions taken based on the information in this article. Violation of FDA regulations can result in serious legal consequences including fines, criminal prosecution, and loss of professional licenses.

Always verify current FDA guidance, consult qualified legal and medical professionals, and review the most recent FDA Bulks Lists and shortage declarations before making any decisions related to peptide compounding.